Nick Leschly vs John Leonard

Nick Leschly

CEO of bluebird bio

BIO: Mr. Nick Leschly has been the Chief Executive Officer and President at bluebird bio, Inc. (alternate name Genetix Pharmaceuticals Inc.) since September 2010. Mr. Leschly served as Interim President at bluebird bio, Inc. until September 2010. He was a Partner at Third Rock Ventures, LLC since 2007. He served as the Chief Business Officer of Agios Pharmaceuticals, Inc. Prior to joining Third Rock, he was the Product and Alliance Leader for Millennium Pharmaceuticals, Inc., and was the Product Leader for VELCADE???, managing a S100M+ global development plan. Mr. Leschly founded and served as the Chief Financial Officer of MedXtend Corporation. He joined Third Rock Ventures in 2007 as a Founding Member and played an integral role in the overall formation, development and business strategy of several of Third Rock's portfolio companies, including Agios Pharmaceuticals (AGIO), Inc. as well as identifying and evaluating new investments. He worked at Accenture Consulting, where he focused on the pharmaceutical industry. Mr. Leschly has been a Director of bluebird bio, Inc. since March 2010. He has been an Independent Director at Synlogic, Inc. since March 2016. Mr. Leschly served as Director of Edimer Pharmaceuticals Inc. He is the Founder and Chairman of The CAVU foundation. He is a Board Member of the Biotechnology Innovation Organization (BIO). Mr. Leschly holds a BS in Molecular Biology from Princeton University and an MBA from Wharton Business School.

John Leonard

CEO of Intellia Therapeutics

BIO: After a 30-year career in pharmaceutical R&D, John Leonard retired from his position as Chief Scientific Officer and Senior Vice President of Research and Development at AbbVie in 2013. Inspired by the opportunity to work with a new therapeutic modality and form a new company, he returned to his life’s passion and joined the Intellia team to direct the research and development effort to make CRISPR/Cas9 technology into a therapeutic reality. John is among the leading R&D executives who have led breakthrough medicines through their discovery, development and launch into blockbuster drugs. While serving as the Global Head of Pharmaceutical R&D at Abbott Laboratories, John oversaw the development of numerous novel therapeutics. His ground-breaking work with HIV protease inhibitors Norvir® and Kaletra® led to new treatment paradigms for AIDS, his years of work with Humira® made it the all-time top-selling drug worldwide and he led significant growth of the R&D pipeline at Abbott and Abbvie. John’s teams were twice recognized with the prestigious Prix Galien Award for excellence in pharmaceutical research. In addition to serving on the Board of Directors of Intellia, John serves on the Board of Directors of IQVIA (NYSE: IQV) and IFM Therapeutics. He received his M.D. from the Johns Hopkins University School of Medicine and completed his residency in Internal Medicine at Stanford University School of Medicine followed by a fellowship at the National Institutes of Health.